Janssen Research & Development to employ Total Brain data for new insights into depression.
Janssen Research & Development to employ Total Brain data for new insights into depression |
| [21-December-2021] |
|
SAN FRANCISCO, Dec. 21, 2021 /PRNewswire/ -- Total Brain today announced that the company will license its International Study to Predict Optimized Treatment for Depression (iSPOT-D) research data to Janssen Research & Development LLC. The company will use Total Brain's iSPOT-D data to support clinical studies and precision drug development efforts to treat depression.
This perpetual license agreement is non-exclusive and makes Janssen R&D the third company to license the iSPOT-D data. "Total Brain's unique standardization and diverse complementary datasets are increasingly proving their value latency at the highest levels of clinical neuroscience," explained Dr. Evian Gordon, Chairman and Chief Medical Officer, Total Brain. iSPOT-D is the largest study of its kind in depression. The study identified objective indicators of treatment response in more than 1,700 depressed individuals using genetics, cognition, brain structure and function imaging, as well as a range of clinical measures, including:
This research study has been published in 55 peer reviewed publications. About Total Brain Total Brain is based in San Francisco and publicly listed in Sydney, AUS (ASX:TTB). Total Brain is a mental health and brain performance monitoring and support platform that has more than 1M registered users. Benefits for healthcare providers include improved patient outcomes, tracking of evidence-based outcomes across the continuum of care, and a reduction in clinician fatigue. Benefits for employers and payers include better mental healthcare access, lower costs and higher productivity. totalbrain.com.
SOURCE Total Brain |
||||||||||
Company Codes: Australia:TTB |
||||||||||
View original content to download multimedia:
